在AML患者中最佳的缓解后巩固疗法
Carlos Jimenez-Chillon1,2, Richard Dillon2,3, Nigel Russell3
1Servicio de Hematologia y Hemoterapia, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Acta haematologica
|November 26, 2023
概括
对急性髓性白血病 (AML) 患者来说,最佳的缓解后治疗对于预防复发至关重要. 定制整合和维护策略,包括化疗,干细胞移植和向药物,可以改善结果.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床治疗学 临床治疗学
背景情况:
- 尽管有进展,但40-85%的急性髓性白血病 (AML) 患者通过化疗实现完全缓解.
- 在AML患者中,高复发率在没有最佳整合和维持疗法的情况下持续存在.
研究的目的:
- 审查急性髓性白血病 (AML) 缓解后治疗的当前策略.
- 根据患者风险分层和特定分子标记指导巩固和维持疗法的选择.
主要方法:
- 审查当前的AML缓解后管理的临床指南和文献.
- 分析包括化疗 (HDAC,IDAC) 和血造干细胞移植 (HSCT) 在内的整合选择.
- 评估维持疗法,包括FLT3抑制剂和针对最小残留疾病 (MRD) 的新兴治疗方法.
主要成果:
- 低中期风险AML患者可能受益于中期剂量cytarabine (IDAC) 或高剂量cyclophosphamide (HDAC) 巩固.
- 高风险的AML患者应考虑与量身定制的调节进行全源造血干细胞移植 (HSCT).
- FLT3突变AML患者从FLT3抑制剂中受益;CC-468是某些不适合整合的患者的选择.
结论:
- 个性化缓解后治疗对于改善AML无复发生存率至关重要.
- 针对最小残留疾病 (MRD) 的新兴治疗方法显示出作为最终疗法或通向全基性HSCT的桥梁的希望.
- 动态风险评估应指导治疗决策,平衡疗效与患者健康和移植资格.
更多相关视频
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
114
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.0K
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:22Bone Marrow Sampling and Transplants
333
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
333